Benzinga

Benzinga

Benzinga

jueves, agosto 27

Karyopharm Therapeutics Inc

KPTINASDAQ
Trade with Public
Trade with Public
$1.98
0.021.02%
Últ. Act.: Aug 27, 9:28 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Karyopharm Therapeutics Financials

Karyopharm Therapeutics (KPTI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
Benzinga Newsdesk

PRO
Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate

Benzinga Newsdesk

PRO
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $137.489 million estimate.
Benzinga Newsdesk

PRO
Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.40) by 11.43 percent. This is a 55.23 percent increase over losses of $(2.77) per
Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
UPDATE: Karyopharm Therapeutics Q4 Adj. EPS $(2.23) Misses $(1.99) Estimate

Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved